In Silico Screen Identifies a New Family of Agonists for the Bacterial Mechanosensitive Channel MscL
Robin Wray1, Paul Blount1, Junmei Wang2
1Department of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
Abstract:
MscL is a highly conserved mechanosensitive channel found in the majority of bacterial species, including pathogens. It functions as a biological emergency release valve, jettisoning solutes from the cytoplasm upon acute hypoosmotic stress. It opens the largest known gated pore and has been heralded as an antibacterial target. Although there are no known endogenous ligands, small compounds have recently been shown to specifically bind to and open the channel, leading to decreased cell growth and viability. Their binding site is at the cytoplasmic/membrane and subunit interfaces of the protein, which has been recently been proposed to play an essential role in channel gating. Here, we have targeted this pocket using in silico screening, resulting in the discovery of a new family of compounds, distinct from other known MscL-specific agonists. Our findings extended the study of this functional region, the progression of MscL as a viable drug target, and demonstrated the power of in silico screening for identifying and improving the design of MscL agonists.
Insights
Researchers discovered new compounds targeting the MscL channel, a potential antibacterial target. In silico screening identified novel MscL agonists, advancing drug development for bacterial infections.
Area of Science:
- Microbiology
- Biophysics
- Drug Discovery
Background:
- Mechanosensitive channel of large conductance (MscL) is crucial for bacterial survival under osmotic stress.
- MscL's role as an emergency release valve and its potential as an antibacterial target are well-established.
- Recent studies identified small molecules that activate MscL, impacting bacterial growth.
Purpose of the Study:
- To identify novel MscL agonists using in silico screening.
- To explore the cytoplasmic/membrane and subunit interfaces as a druggable pocket for MscL modulation.
- To advance the development of MscL as a viable antibacterial drug target.
Main Methods:
- In silico screening of compound libraries against the MscL binding site.
- Characterization of newly identified MscL agonists.
- Evaluation of the impact of compounds on bacterial cell growth and viability.
Main Results:
- Discovery of a new family of MscL-specific agonists through in silico screening.
- Identification of a distinct binding site compared to previously known MscL modulators.
- Demonstration that these compounds decrease bacterial cell growth and viability.
Conclusions:
- The cytoplasmic/membrane and subunit interfaces represent a promising target for MscL modulation.
- In silico screening is an effective strategy for discovering and optimizing MscL agonists.
- These findings support the progression of MscL as a viable antibacterial drug target.
